Completed OBSERVATIONAL NCT06031194

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Sponsor: Ohio State University Comprehensive Cancer Center

Conditions Central Nervous System Lymphoma Diffuse Large B-Cell Lymphoma

Updated 9 times since 2023 Last updated: Dec 31, 2025 Started: May 10, 2023 Primary completion: Nov 5, 2025 Completion: Dec 23, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Central Nervous System Lymphoma and Diffuse Large B-Cell Lymphoma and is currently completed. Ohio State University Comprehensive Cancer Center leads this study, which shows 9 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Feb 2026 — Present [monthly]

Completed

Status: Active Not Recruiting → Completed
Dec 2025 — Feb 2026 [monthly]

Active Not Recruiting
Oct 2025 — Dec 2025 [monthly]

Active Not Recruiting

Status: Recruiting → Active Not Recruiting
May 2025 — Oct 2025 [monthly]

Recruiting
Mar 2025 — May 2025 [monthly]

Recruiting

▶ Show 4 earlier versions

Sep 2024 — Mar 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Dec 2023 — Jul 2024 [monthly]

Recruiting
Oct 2023 — Dec 2023 [monthly]

Recruiting

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ohio State University Comprehensive Cancer Center

Data source: Ohio State University Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States